Health stocks were down - as were the broader markets - amid the kickoff of third-quarter results.The NASDAQ and Amex biotechnology indices were down 1.1% and 1.7%, respectively. Big biotech Amgen ( AMGN - Get Report) and Biogen ( BIIB - Get Report) were down 2.7% and 0.9%. Pharmaceutical stocks fared better than their biotech cousins -- the Amex pharma index was up just 0.8%, One component of the pharma index, Eli Lilly ( LLY - Get Report) said Tuesday that it has commenced the tender offer for all outstanding shares of ImClone ( IMCL) at $70 a share. The $6.5 billion deal was announced last week. ImClone shares rose 82 cents, or 1.2%, at $67.82, while Lilly's shares fell 88 cents, or 2.4%, to $34.98 on Tuesday. One of the first health stocks to release earnings, Johnson & Johnson ( JNJ - Get Report)reported income of $3.31 billion, or $1.17 a share, on revenue of $15.9 billion. Results topped expectations of analysts surveyed by Thomson Reuters who'd pegged $1.11 a share on $15.69 billion. Shares were up $1.48, or 2.4%, at $64.14. Elsewhere - in a few analyst actions -- Needham upped its rating for medical technology company and device maker Stryker ( SYK - Get Report) to buy from hold with a $66 price target. That stock was trading up $1.33, or 2.3%, at $59.86. Also, Cantor Fitzgerald significantly upped its price target for Sequenom ( SQNM), which is developing a non-invasive prenatal test for Down syndrome to $42 from $29. Shares added 34 cents, or 1.8%, to $19.76. Look for earnings from Abbott Laboratories ( ABT - Get Report)and St. Jude Medical ( STJ) before the market open on Wednesday. Analysts, on average, are expecting 77 cents a share on revenue of $7.35 billion for the third quarter from Abbott and 57 cents a share on $1.07 billion in revenue from St. Jude. After the close on Wednesday, look for third quarter results from Amylin ( AMLN). The Street expects Amylin to report a loss of 50 cents a share on $229 million in revenue.
More from Investing
Apple Arcade Could Be a Big Hit, But Its Value Won't Be Realized Overnight
A low price point plus one-month free trial could make Apple Arcade an appealing option for millions of gamers worldwide, but old habits could still prove hard to break.
State Attorneys General May Probe Facebook, Google: Report
Move would add another antitrust probe to those already faced by large tech firms.
Sonos Resonates With Investors on Raymond James Upgrade to Strong Buy
Digital-home-audio-device maker is well-positioned relative to peers, the firm says.